IL22 and necrotizing enterocolitis: Genetic engineering technologies, such as CRISPR/Cre and CAR-T cells (76, 129–131), may facilitate the production of IL-22-producing γδ T and/or MAIT cells, even iCD8α IELs, for cell-based immunotherapy for NEC.